AFP is a well-known biomarker for HCC, and AFP reduction was recently associated with better outcomes among patients with baseline AFP ≥ 400 μg/L or with a history of hepatitis B or C virus or alcohol use [53]. Here, AFP is linked to hepatocellular carcinoma.